ClinicalTrials.gg
CompletedNCT02020369Updated Jun 14, 2017Results posted

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

A Phase 3 interventional study of Coagulation Factor VIIa (Recombinant) in Hemophilia A With Inhibitors and Hemophilia B With Inhibitors, sponsored by rEVO Biologics. Completed at 17 sites in 10 countries. Open to male participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by rEVO Biologics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
9th of 19
27 · median 24
Started
2014
with 1 other
Phase 3
5 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
2 of 20
rEVO Biologics

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 16th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX

Read the detailed description

This was a global, multicenter, Phase III, prospective, open-label, randomized, crossover study. After obtaining informed consent and performance of screening procedures, patients who met all inclusion and exclusion criteria were randomized to one of two treatment regimens as follows:

  • 75 µg/kg treatment regimen
  • 225 µg/kg treatment regimen

For each treatment regimen there were two phases:

  • Phase A (Initial phase)
  • Phase B (Treatment phase)

The assigned treatment regimen was the dose administered in Phase A and was the starting dose in Phase B.

03

Conditions studied

  • Hemophilia A With Inhibitors
  • Hemophilia B With Inhibitors
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be male with a diagnosis of congenital hemophilia A and/or B of any severity
  • have one of the following:
  • a positive inhibitor test Bethesda Unit (BU) ≥ 5 (as confirmed at screening by the institutional lab), OR
  • a BU\<5 but expected to have a high anamnestic response to FVIII or FIX, as demonstrated from the subject's medical history, precluding the use of Factor VIII or IX products to treat bleedings, OR
  • a BU\<5 but expected to be to increased dosing of FVIII or FIX, as demonstrated from the subject's medical history, precluding the use of Factor VIII or IX products to treat bleedings
  • be 12 years or older, up to and including 75 years of age (NOTE: different age restrictions may apply per local regulation and/or ethical considerations)
  • have at least 3 bleeding episodes of any severity in the past 6 months be capable of understanding and willing to comply with the conditions of the protocol
  • have read, understood and provided written (patient and/or parent(s)/legal guardian(s) if \<18 years of age)

Exclusion criteria

Exclusion Criteria:

  • have any coagulation disorder other than hemophilia A or B
  • be immuno-suppressed (i.e., the patient should not be receiving systemic medication, cluster of differentiation 4 (CD4) counts at screening should be >200/µl)
  • have a known allergy or to rabbits
  • have count \<100,000/mL
  • have had within one month prior to first administration of the study drug in this study a major surgical procedure (e.g. orthopedic, abdominal)
  • have received an drug within 30 days of the first study drug administration, or is expected to receive such drug during participation in this study
  • have a hepatic ( and/or alanine aminotransferase (ALT) >3 times the ) and/or renal impairment (creatinine >2 times the upper limit of normal)
  • have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, , deep venous thrombosis or pulmonary embolism) within 2 years prior to first dose of study drug, or current (NYHA) functional classification score of stage II -IV
  • have an active (those with non-melanoma skin cancer are allowed)
  • have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome (e.g., a history of non-responsiveness to bypassing products).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    FVIIa: 75 µg/kg first, then 225 µg/kg

    Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.

    Biological: Coagulation Factor VIIa (Recombinant)

  • Experimental
    FVIIa: 225 µg/kg first, then 75 µg/kg

    Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.

    Biological: Coagulation Factor VIIa (Recombinant)

Interventions

  • A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX

06

What researchers measure

Primary outcomes

  1. Proportion of Successfully Treated Mild/Moderate Bleeding Episodes

    For the primary efficacy endpoint, successful treatment of a bleeding episode was defined as a combination of the following: * "Good" or "Excellent" response noted by the patient * Study drug treatment: No further treatment with study drug beyond timepoint for this bleeding episode * No other hemostatic treatment needed for this bleeding episode * No administration of blood products that would indicate continuation of bleeding beyond timepoint * No increase of pain beyond timepoint that could not otherwise be explained

    Time frame: 12 hours after first administration of study drug

Secondary outcomes

  1. Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported "Good" or "Excellent" Responses at 12 Hours

    Based on Patient-Reported "Good" or "Excellent" responses as per the below descriptions: Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug. Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.

    Time frame: at 12 hours

  2. Time to Assessment of a "Good" or "Excellent" Response of Mild/Moderate Bleeding Episodes by the Patient

    Categories of Response to Treatment are Described as Follows: None: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed. Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug. Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.

    Time frame: Within 24 hours of Bleeding Episode

  3. Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode

    Time frame: Within 24 hours of Bleeding Episode

  4. Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode

    Time frame: Through study completion

07

Results

Posted Jun 14, 2017

Participant flow

Participant flow — Overall Study
MilestoneFVIIa: 225 µg/kg First, Then 75 µg/kgFVIIa: 75 µg/kg First, Then 225 µg/kg
Started1413
Completed1111
Not completed32

Outcome measures

PrimaryProportion of Successfully Treated Mild/Moderate Bleeding Episodes

For the primary efficacy endpoint, successful treatment of a bleeding episode was defined as a combination of the following: * "Good" or "Excellent" response noted by the patient * Study drug treatment: No further treatment with study drug beyond timepoint for this bleeding episode * No other hemostatic treatment needed for this bleeding episode * No administration of blood products that would indicate continuation of bleeding beyond timepoint * No increase of pain beyond timepoint that could not otherwise be explained

Time frame:
12 hours after first administration of study drug
Reported as:
Number · Proportion of Success of BEs
Proportion of Successfully Treated Mild/Moderate Bleeding Episodes
Proportion of Success of BEsFVIIa 75 µg/kgFVIIa 225µg/kg
Proportion of Successfully Treated Mild/Moderate Bleeding Episodes.849 (.740 to .957).932 (.881 to .983)
SecondaryProportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported "Good" or "Excellent" Responses at 12 Hours

Based on Patient-Reported "Good" or "Excellent" responses as per the below descriptions: Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug. Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.

Time frame:
at 12 hours
Reported as:
Number · Pt-reported proportion success of BEs
Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported "Good" or "Excellent" Responses at 12 Hours
Pt-reported proportion success of BEsFVIIa: 75 µg/kgFVIIa: 225 µg/kg
Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported "Good" or "Excellent" Responses at 12 Hours0.857 (0.750 to 0.964)0.937 (0.888 to 0.986)
SecondaryTime to Assessment of a "Good" or "Excellent" Response of Mild/Moderate Bleeding Episodes by the Patient

Categories of Response to Treatment are Described as Follows: None: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed. Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug. Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.

Time frame:
Within 24 hours of Bleeding Episode
Reported as:
Median · Hours
Time to Assessment of a "Good" or "Excellent" Response of Mild/Moderate Bleeding Episodes by the Patient
HoursFVIIa: 75 µg/kgFVIIa: 225 µg/kg
Time to Assessment of a "Good" or "Excellent" Response of Mild/Moderate Bleeding Episodes by the Patient5.98 (5.95 to 6.00)3.00 (NA to NA)
SecondaryNumber of Administrations of Study Drug Per Mild/Moderate Bleeding Episode
Time frame:
Within 24 hours of Bleeding Episode
Reported as:
Mean · Number of Administrations of Study Drug
Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode
Number of Administrations of Study DrugFactor VIIa: 75 µg/kgFVIIa: 225 µg/kg
Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode2.5 ± 1.751.4 ± 0.96
SecondaryTotal Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode
Time frame:
Through study completion
Reported as:
Mean · µg/kg per bleeding episode
Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode
µg/kg per bleeding episodeFVIIa: 75 µg/kgFVIIa: 225 µg/kg
Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode187.868 ± 131.7982252.963 ± 78.9732

Adverse events

Collected over Adverse event data was collected 2 years, 3 months, 2 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Coagulation Factor VIIa (Recombinant): 75 µg/kg—1/25 (4%)3/25 (12%)
Coagulation Factor VIIa (Recombinant): 225 µg/kg—0/25 (0%)3/25 (12%)
Most frequent serious events
Most frequent serious events
EventCoagulation Factor VIIa (Recombinant): 75 µg/kgCoagulation Factor VIIa (Recombinant): 225 µg/kg
acute tonsillitisInfections and infestations1/250/25
subarachnoid hemorrhageNervous system disorders1/250/25
Most frequent other events
Most frequent other events
EventCoagulation Factor VIIa (Recombinant): 75 µg/kgCoagulation Factor VIIa (Recombinant): 225 µg/kg
NasopharyngitisInfections and infestations1/252/25
HeadacheNervous system disorders2/251/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)FVIIa 75 µg/kg First, Then 225 µg/kgFVIIa 225 µg/kg First, Then 75 µg/kgTotal
<=18 years235
Between 18 and 65 years111122
>=65 years000
Age, Continuous
Age, Continuous(years)FVIIa 75 µg/kg First, Then 225 µg/kgFVIIa 225 µg/kg First, Then 75 µg/kgTotal
Mean31.8 ± 12.1030.1 ± 12.9831.0 ± 12.35
Sex/Gender, Customized
Sex/Gender, Customized(participants)FVIIa 75 µg/kg First, Then 225 µg/kgFVIIa 225 µg/kg First, Then 75 µg/kgTotal
Male (n)131427
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FVIIa 75 µg/kg First, Then 225 µg/kgFVIIa 225 µg/kg First, Then 75 µg/kgTotal
Hispanic or Latino101
Not Hispanic or Latino121426
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FVIIa 75 µg/kg First, Then 225 µg/kgFVIIa 225 µg/kg First, Then 75 µg/kgTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American011
White121325
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FVIIa 75 µg/kg First, Then 225 µg/kgFVIIa 225 µg/kg First, Then 75 µg/kgTotal
Russian Federation235
United States224
Ukraine6612
Poland101
United Kingdom011
Georgia112
Bulgaria112
08

Study locations

17 sites
  • Orthopaedic Hemophilia Treatment Center
    Los Angeles, California 90007, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • University of Colorado Hemophilia and Thrombosis Center
    Aurora, Colorado 80045, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Minnesota Medical Center Fairview
    Minneapolis, Minnesota 55455, United States
  • Republican Research Center for Radiation Medicine and Human Ecology
    Gomel, Belarus
  • Specialized Hospital for Active Treatment of Hematological Diseases
    Sofia, Bulgaria
  • LTD HEMA
    Tbilisi, Georgia
  • Chaim Sheba Medical Center, Tel-hashomer hospital
    Ramat Gan, 5261, Israel
  • Institute of Hematology and Transfusion Medicine
    Warsaw, Poland
  • Sandor SRL
    Bucharest, Romania
  • Kirov Research Institute of Hematology and Blood Transfusion
    Kirov, Russian Federation
  • Hematology Research Center
    Moscow, Russian Federation
  • City Outpatient Clinic #37
    Saint-Petersburg, Russian Federation
  • Kyiv City Clinical Hospital #9
    Kyiv, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine of Academy of Medical Sciences of Ukraine
    Lviv, Ukraine
  • Basingstoke and North Hampshire Hospital, Hemophilia, Hemostasis and Thrombosis Center
    Basingstoke, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jul 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 24, 2013
Start
Apr 2014
Primary completionActual
Jul 2015
CompletionActual
Aug 2015
Results first posted
Jun 14, 2017
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02020369
Lead sponsor
rEVO Biologics
Collaborators
Laboratoire français de Fractionnement et de Biotechnologies
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Apr 2014
Primary completion
Jul 2015
Completion
Aug 2015
Results posted
Jun 14, 2017
Last update
Jun 14, 2017

Study contacts

Jean Francois Schved, MD
principal investigator · Saint Eloi Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion